Para IV Pipeline Analysis of Indian Pharma Companies
As we near the patent cliff of 2014, many of the Indian companies are choosing the Para IV route to grab a higher market share, both in value and volume. The impact of Indian companies can be gauged by the fact that Indian companies account for more than 50% of the ongoing litigations and they have secured 180-day exclusivity in 6 of the world’s top 11 products under litigation.
This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the product for every company. Each product is studied as a case study and its opportunity is evaluated based on various aspects of the patent litigation.
The report will give you a clear understanding of the impact on the earnings of each of the Indian companies.
The report is priced at $400. If interested, please reply to this e-mail and we will get back to you.
This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the product for every company. Each product is studied as a case study and its opportunity is evaluated based on various aspects of the patent litigation.
The report will give you a clear understanding of the impact on the earnings of each of the Indian companies.
The report is priced at $400. If interested, please reply to this e-mail and we will get back to you.
COMPANIES MENTIONED
Aurobindo, Cadila, Dr. Reddy's, Glenmark, Intas, Lupin, Natco, Orchid, Ranbaxy, Sun Pharma, Torrent, Wockhardt
Aurobindo, Cadila, Dr. Reddy's, Glenmark, Intas, Lupin, Natco, Orchid, Ranbaxy, Sun Pharma, Torrent, Wockhardt
